Alzamend Neuro Reports Positive Topline Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study; AL001 Achieves Bioequivalence and Demonstrates Superior Brain Delivery Across All
Go back to Alzamend Neuro Reports Positive Topline Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study; AL001 Achieves Bioequivalence and Demonstrates Superior Brain Delivery Across All| (NASDAQ: ALZN) | Delayed: 1.31 +0.09 (7.38%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.22 | 52 Week High | $ | |||
| Open | $1.18 | 52 Week Low | $ | |||
| Day High | $1.36 | P/E | N/A | |||
| Day Low | $1.18 | EPS | $ | |||
| Volume | 302,364 | |||||
